



March 17, 2016

ProPhotonix Limited  
("ProPhotonix" or "the Company")

## **ProPhotonix extends COBRA CURE FX Series with Higher Power UV Curing System**

*Compact, UV LED Solution featuring an innovative stackable design, field replaceable window and other unique features*

ProPhotonix Limited, (London Stock Exchange - AIM: PPIX; OTC: STKR), a high technology designer and manufacturer of LED illumination systems and laser diode modules, announces an extension to its UV LED Curing systems, the COBRA Cure FX2, which provides more intense UV curing critical to the printing industry, coatings industry, 3D printing, and other applications.

UV LED Curing systems offer significant design and operating advantages over traditional UV lamp technology. LED systems reduce maintenance costs, use less energy, control curing intensity, and provide a "cold cure" which is ideal for heat sensitive substrates. In addition, LED technology offers a more sustainable solution than traditional technologies with no ozone emissions or mercury content.

The [COBRA Cure FX](#), announced in September 2015, produces a uniform line with a peak irradiance of  $6 \text{ W/cm}^2$  and peak energy density (dose) of  $5 \text{ J/cm}^2$ . The COBRA FX2 delivers best-in-class intensities up to  $8.4 \text{ W/cm}^2$  and energy densities up to  $17.5 \text{ J/cm}^2$ . Its design builds on the advantages of LED curing systems by incorporating elements that ensure a consistent, reliable cure over the lifetime of the system.

In certain operating environments, residue builds up on the emission window reducing the intensity of the light and causing a degradation of system performance. The COBRA Cure FX2 includes a patent pending field-replaceable window that requires no special tools which eliminates downtime while delivering consistent system output.

The COBRA Cure FX2 is scalable without any drop in intensity from module to module ensuring consistent edge-to-edge illumination. It is designed to monitor and drive each LED segment providing consistent intensity control across the entire illumination area. Wavelength options include 365nm, 385nm, 395nm, and 405nm configurations as well as integrated multi-wavelength options.

Tim Losik, CEO and President of ProPhotonix, said “ProPhotonix (IRL) Limited has been a pioneer in LED technology since 1994 and a provider of UV LED solutions since 2006. As an early adopter of LED chip-on-board technology, ProPhotonix provides high intensity illumination across all LED wavelengths - including UV. The FX2 adds to our broad range of UV LED products providing more illumination options for our customers. Estimates are that market demand for UV LED systems will grow at nearly 40% per annum through 2019 to \$500 million. We are uniquely positioned to significantly participate in this high growth market and deliver ongoing enhancements to our customers.”

For more information about COBRA Cure FX2, visit [www.prophotonix.com/products/UV-Solutions](http://www.prophotonix.com/products/UV-Solutions).



### **COBRA Cure FX2 – UV LED Curing System**

#### **Contact:**

#### **ProPhotonix Limited**

Simon Stanley, Managing Director, Ireland

**+353-21500-01300**

Sales

**[sales@prophotonix.com](mailto:sales@prophotonix.com)**

#### **About ProPhotonix**

ProPhotonix Limited, headquartered in Salem, New Hampshire, is a high technology designer and manufacturer of diode-based laser modules and LED systems for industry leading OEMs and medical equipment companies. In addition, the Company distributes premium diodes for Ushio (formerly Oclaro), Osram, QSI, Panasonic, and Sony. The Company serves a wide range of markets including the machine vision, industrial inspection, security, and medical markets. ProPhotonix has offices and subsidiaries in the U.S., Ireland, U.K., and Europe. For more information about ProPhotonix and its innovative products, visit the Company's web site at [www.prophotonix.com](http://www.prophotonix.com)

#### **Cautionary Statement**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact, including without limitation, those with respect to ProPhotonix's goals, plans and strategies set forth herein are forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: uncertainty that cash balances may not be sufficient to allow ProPhotonix to meet all of its business goals;

uncertainty that ProPhotonix's new products will gain market acceptance; the risk that delays and unanticipated expenses in developing new products could delay the commercial release of those products and affect revenue estimates; the risk that one of our competitors could develop and bring to market a technology that is superior to those products that we are currently developing; and ProPhotonix's ability to capitalize on its significant research and development efforts by successfully marketing those products that the Company develops. Forward-looking statements represent management's current expectations and are inherently uncertain. All Company, brand, and product names are trademarks or registered trademarks of their respective holders. ProPhotonix undertakes no duty to update any of these forward-looking statements.